The above two studies demonstrated that almonertinib significantly improved PFS and DOR in patients with EGFR-mutated advanced NSCLC both as a first- and second-line treatment, and was well tolerated by patients (13). This evidence concerns the gene EGFR and non-small cell lung carcinoma.